In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Infinity Announces Hedgehog Pathway Inhibitor Agreement With AstraZeneca
Peregrine Reacquires Rights to Oncolym
Neurocrine reacquires worldwide marketing rights to MSP771
Refocus Group reacquires rights to implant and surgical procedure from CIBA Vision
D-Pharm reacquires DP-VPA from Shire
Infinity selects Evotec as partner
Cancer Research Technology and The Institute of Cancer Research complete licence with Vernalis
Targeted Genetics reacquires rights to Cystic Fibrosis program
INFINITY ANNOUNCES SMALL MOLECULE COLLABORATION WITH NOVARTIS